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Abstract
This is our 7th annual literature review on mechanical circulatory support (MCS)
devices.
Our previous reports were well received by the readers. The full text of the reviews
for 2014, 2015, 2016, 2017, 2018, 2019 1-6 were downloaded 807, 843, 638, 827,
841, and 199 times, respectively.
In this review, we summarized the most interesting and important, from our
standpoint, publications covering MCS from 2020. There may be some slight overlap
with the end of 2019 because some papers were published online first, and the year
of the publication changed when they became available in print.
For the fourth time this year, we added a section on extracorporeal membrane
oxygenation (ECMO), which primarily addresses new developments in veno-arterial
(V-A) ECMO.
Readers who wish to supplement this review, argue with the author’s statements, or
express their opinions are encouraged to do so by sending letters to the editor at
mguglin@iu.edu.
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Outcomes
In 2020, the focus of the annual report from the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS) was on the comparison
of major outcomes between the axial-flow HeartMate II (HMII) (Abbott Laboratories,
Abbott Park, IL), the centrifugal-flow Heartware (Medtronic, Minneapolis, MN), and
the centrifugal-flow with full magnetic levitation HeartMate 3 (HM3) (Abbott
Laboratories, Abbott Park, IL) devices. There has been a massive shift in the type
of pumps used. While in 2014, 70.1% of implants were axial flow devices, their share
was reduced to 2.1% in 2019.7
The overall survival with current-generation left ventricular assist devices (LVADs)
continues to be favorable, with a 30-day mortality of only 5% and 1-year survival of
82%. No differences in 2-year survival (72% vs. 74%) were noted between those
who received LVADs from 2014-2016 and those implanted between 2017-2018.7
There was no significant difference in survival between the HMII and Heartware, but
the HM3 had a 1-year survival of 87%, which was significantly higher in an
unadjusted comparison with the Heartware (79%, P < .001).7
Importantly, apart from right heart failure (HF), the HM3 had a lower complication
risk. Freedom from the first stroke at 1 year, regardless of severity, was 88% for
HMII, 84% for Heartware, and 93% for HM3. The gastrointestinal (GI) bleeding rate
was 25% for HMII, 20% for Heartware, and 12% for HM3 for the first year postimplant. Beyond the first year, centrifugal-flow devices had a lower incidence of GI
bleeding as compared to axial flow devices. Major infection was the most common
adverse event, with only 60% of HMII, 57% of Heartware, and 67% of HM3
implantations being free of a major infection at 1 year. Freedom from right HF at one
year was higher in HMII (71%) than in Heartware (62%) or HM3 (66%). The authors
of the report underscored that the analysis coming from a non-randomized registry
should be taken with caution.7
In addition, there was a major change in the balance between bridge-to-transplant
(BTT) and destination therapy (DT) strategies. In 2014, less than half (46.6%) of the
LVADs were implanted as DT; the share increased to 70.2% by 2019.7 This may
reflect the change in the organ allocation system implemented by United Network
for Organ Sharing (UNOS) in October of 2018 that made it increasingly difficult to
transplant candidates who are stable on LVAD support and are without any major
complications.
For those who received the LVAD as a BTT strategy, 33% received a transplant by
1 year, 50% by 2 years, and 61% by 5 years. In contrast, for those whose LVAD
was implanted as DT, fewer than 20% received a transplant by 5 years.7
Two smaller-scale analyses compared the outcomes of patients with Heartware and
HM3s.
The first was a single-center, retrospective study where higher-risk patients
(INTERMACS level I-II) received Heartware (73%) versus HM3 (57%, P = .018).
Patients with HVADs were more likely to experience cerebral bleedings (hazard ratio
[HR] 6.79 [1.43-32.20], P = .016). Also, the incidence of hemocompatibility-related
adverse events was significantly higher in the HVAD group (1.28 vs. 0.7 events per
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patient-year, P < .001). The 1-year survival was similar in the HVAD and HM3
groups (62.2% vs 66.7%, respectively).8
In the second single-center study, patients were retrospectively matched by several
major clinical parameters including age, sex, and the INTERMACS profile. During a
median follow-up at 15.3 months, 29.1% and 24.1% of patients died in the HVAD
and HM3 groups, respectively. The HR for mortality was 0.84 (nonsignificant).
Freedom from cerebrovascular events did not differ between study groups. The risk
of driveline infection was significantly lower in the HM3 than in the HVAD group (HR
= 0.54; 95% CI: 0.35-0.84; P = .006). In addition, 8 patients with an HVAD and 0
with HM3 developed a pump thrombosis during follow-up (P = .148).9

Device-Specific Outcomes
Total Artificial Heart
In a retrospective analysis of 217 patients who received a total artificial heart
(SynCardia Systems, Tucson, AZ) at one of 6 high-volume, North American centers,
63.5% of patients later underwent cardiac transplantation, and 34.5% of recipients
died. The mean time on support before the transplantation averaged 181 ± 179 days
(range: 0-849). The overall survival in the entire cohort was 75%, 64%, and 58% at
1, 2, and 5 years, respectively.10

HeartMate 3 (HM3)
The prospective, observational, multi-national ELEVATE (Evaluating the HeartMate
3 with Full MagLev Technology in a Post-Market Approval Setting) registry was
designed to study long-term outcomes of the HM3 in a real-world population in
Europe and the Middle East. Survival at 2 years post-implant was 83%, with a
favorable profile of adverse events. Specifically, the incidence of major
complications was 10.2% for stroke, 9.7% for GI bleeding, and 1.5% for pump
thrombosis. The outflow graft twists were found in 3.5% of patients.11
As more and more evidence confirm a low rate of pump thrombosis in HM3,
additional studies are being done to test the optimal level of anticoagulation in
patients supported with this device. In a sub-study of the MOMENTUM 3
(Multicenter Study of MagLev Technology in Patients Undergoing Mechanical
Circulatory Support Therapy with HeartMate 3) trial, a comparison between 325 mg
and 81 mg of aspirin a day revealed no difference in two-year survival, bleeding
events, pump thrombosis, stroke, and peripheral arterial thromboembolic events.
There were also no differences in survival free from hemorrhagic (usual-dose:
54.4% vs low-dose: 51.7%, P = .42) or thrombotic (usual-dose: 76.8% vs low-dose:
75.7%, P = .92) events.12
A new randomized controlled trial, The ARIES HM3 Pump IDE Study (The
Antiplatelet Removal and Hemocompatibility EventS with the HeartMate 3 Pump
IDE Study, NCT04069156) is poised to show whether aspirin at any dose has a role
in HM3 management. Meanwhile, Lim et al.13 reported on the outcomes of patients
who were given a choice of being on aspirin and warfarin or on warfarin only. Their
study included 90 patients supported by a HM3. The majority (53/90) of subjects
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opted out of aspirin after a median of 126 days post-implant, and 27/90 continued
on both aspirin and warfarin. The median duration of warfarin monotherapy was 624
days, and 41/53 patients remained on warfarin alone for over a year. The 2-year
survival for the whole cohort was 82%, and the 2-year survival conditional on
hospital discharge was 93%. There was a total of 2 patients who had ischemic
strokes after the division into aspirin or no aspirin, one per each arm. In other words,
aspirin in HM3 patients seems to be unnecessary with a randomized study pending.
Imamura et al.14 studied the association of the geometry of the LVAD position with
outcomes of patients. For HM3, a coronal angle (which is the angle between the
axis of the inflow cannula and horizontal line, Figure 1) of ≤ 28 degrees was found
to be the optimal placement. Such an angle, in comparison with angles of more than
28 degrees, was associated with better cardiac unloading and the following:
•
•
•
•
•
•

lower central venous pressure (CVP) (P = .030)
lower pulmonary capillary wedge pressure (P = .027)
smaller left ventricular (LV) size (P = .019)
smaller right ventricular (RV) size
better RV function
lower 1-year cumulative incidence of death or HF readmissions (P = .008).

Figure 1. Coronal angle of HM3 cannula
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Heartware Ventricular Assist Device
In terms of surgical placement of the device, for Heartware, the coronal angle less
than 65 degrees was associated with better hemodynamics and fewer HF
readmissions. The greater angle was associated with elevated intracardiac
pressures, lower pulmonary artery pulsatility index (P < .05), and reduced RV
function by echocardiography. Freedom from hemocompatibility-related events also
tended to be lower in the wide-angle (>65 degrees) group (24% vs 62%; P = .11).
The rate of GI bleeding was significantly higher in the wide-angle group (0.90
events/year vs 0.40 events/year; P = .013). The rates of stroke and pump thrombosis
were statistically comparable.15
Speaking of broader outcomes, in a multicenter, prospective registry collecting postapproval data on Heartware as a BTT from several European and Australian
centers, a Kaplan-Meier survival through 7 years was 51%. Through 6 years,
freedom from any stroke was 82%, while freedom from severely disabling stroke
was 89%.16
In a single-center study of 103 patients who received an HVAD, the mean survival
was 2.05 ± 2.14 years.17 The Kaplan-Meier analysis showed an overall survival rate
of 69.7%, 56.7%, 46.0%, and 25.0% at 1, 2, 4, and 8 years, respectively. Subanalysis of the BTT patients showed a mean survival of 2.45 ± 2.29 years with a
survival rate of 85.1%, 75.1%, 67.2%, and 44.8% at 1, 2, 4, and 8 years,
respectively. For DT, mean survival was 2.18 ± 1.91 years with a survival rate of
67.9%, 49.0%, and 25.1% at 1, 2, and 4 years, respectively.17
Although HM3 can be used for biventricular support with one pump per side, there
is more experience with the HVAD in this configuration. According to data from
several centers, survival at 1 and 2 years was 56% and 47%, respectively, with no
difference between the right atrial and RV implantation of the right-sided device.18
However, per systematic literature review, Kaplan-Meier analysis showed a higher
1-year survival with implantation in the right atrial than the RV (91.7% vs 66.2% P =
.036). Pump thrombosis occurred at a similar rate of 30%.19
While the HM3 pump has a built-in pulsatility with the slight speed change every 2
seconds, the HVAD has a somewhat similar function, the Lavare cycle, which has
to be activated. In essence, once a minute, the set speed decreases by 200
revolutions per minute (rpms) for 2 seconds, then it increases to 200 rpms above
the set speed for one second, and then returns to the baseline (Figure 2). This cycle
is designed to automatically increase both ventricular and pump washing to prevent
thrombosis. In a non-randomized study, Lavare was activated in some patients and
left inactive in the rest. Surprisingly, both the incidence and rate of pump thrombosis
were significantly higher for the “Lavare On” group (incidence of 31.8 % vs 7.9%, P
= .02). There was a non-significant trend to a higher rate of strokes in patients with
the Lavare cycle, and the incidence of GI bleeds was similar. The authors
hypothesized that late activation of Lavare disturbed a stable but potentially
prothrombotic pannus at the inflow cannula; they concluded that this feature, if used
at all, should be activated immediately after the HVAD implantation.20
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Figure 2. The Lavare cycle

Recovery
Cardiac recovery on LVAD support that allows for the LVAD to be inactivated via
surgical removal or decommissioning percutaneously is one of the most popular
topics in the MCS field, and there were major advancements in 2020. Percutaneous
LVAD exclusion can be accomplished with the occluder deployed at both proximal
and distal portions of the outflow graft or in the inflow graft, and patients usually
continue to take warfarin for prevention of thromboembolism.21
In general, recovery remains rare with less than 5% of LVADs being explanted per
the INTERMACS.7 In the European Registry for Patients with Mechanical Circulatory
Support, successful LVAD explantation due to myocardial recovery occurred in
1.5% of patients.22 Patients who recovered, compared with those who did not, were
younger (44 vs. 56 years, P < .001), had a shorter duration of HF (P < .001), and
had a non-ischemic etiology (only 9% of recovered patients had ischemic
cardiomyopathy vs. 41.8% in patients without recovery, P < .001).22
It is widely known that when an LVAD unloads the LV, the ventricle decreases in
size and left ventricular ejection fraction (LVEF) improves, which mostly occurs
within the first 6-12 months after the implant.23 On the tissue level, however, full
recovery is uncommon. When cardiac specimens from patients without cardiac
disease, with severe cardiomyopathy, and with cardiomyopathy on LVAD support
were examined for cardiac fibrosis, the collagen content was significantly higher in
failing hearts, both without mechanical unloading and on LVAD support, than in
healthy hearts.24
Historically, in two single-center studies, the rate of myocardial recovery was
remarkably high. In the first study from 2006, which included young patients who
received an LVAD for non-ischemic cardiomyopathy, 73% (11/15) of them later had
the LVAD explanted due to recovery. All patients in that study were on a pulsatileflow LVAD. The cumulative rate of freedom from HF was 100% and 88.9% at 1 and
4 years post-explantation, respectively. In addition to standard HF medications,
patients received a beta2- adrenergic-receptor agonist and clenbuterol in hope of
preventing myocardial atrophy.25 However, high-dose clenbuterol, given to another
group of patients on LVAD support, failed to produce any changes in the
myocardium, although it resulted in an increase in skeletal muscle mass.26
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In the second study, published in 2011, a similar combination of angiotensine
receptor enzyme inhibitors (ACE), angiotensine receptor blockers (ARBs), beta
blockers (BB), aldosterone antagonists, and clenbuterol was given to 20 young (35.2
± 12.6 years), non-ischemic patients on a continuous-flow LVAD. Explantation
occurred in 63.2% of patients. Over a year later, LVEF in post-explant patients
remained normal at 58.1 ± 13.8%.27
In 2020, results from the prospective, multicenter, non-randomized RESTAGE-HF
study (Remission from Stage D Heart Failure) were published. In 40 non-ischemic
patients (from six different clinical sites) on HMII support, the LVAD speed was
optimized, and regular echocardiograms were performed at reduced LVAD speed
(6000 rpms, no net flow) to test underlying myocardial function. Remarkably, cases
of recovery occurred in all participating sites.28 The patient group was relatively
young (aged 35.1 ± 10.8 years). The medical regimen consisted of lisinopril (20 mg
twice a day), carvedilol (50 mg twice a day), spironolactone (25 mg daily), digoxin
(125 mcg daily), and losartan (150 mg daily). Unlike in the first two studies,
clenbuterol was not used. The primary end point was the proportion of patients with
sufficient improvement of myocardial function to reach criteria for explantation within
18 months with sustained remission from HF (freedom from transplant/VAD/ death)
at 12 months. Overall 50% (18/36) of patients receiving the protocol were explanted
within 18 months. For those that were explanted, the pre-explant LVEF was 57 ±
8%; end-diastolic diameter was 4.81 ± 0.58 cm; end-systolic diameter was 3.53 ±
0.51 cm; pulmonary capillary wedge pressure was 8.1 ± 3.1 mm Hg; and pulmonary
artery saturation was 63.6 ± 6.8% at 6000 rpms. Of note, 4 patients dropped out for
unrelated reasons. After explantation, survival free from VAD or transplantation was
90% at 1-year and 77% at 2 and 3 years.

Candidate Selection
Several tests, that are traditionally included in the panel of parameters checked
before accepting a candidate for LVAD implant, may not be as helpful as assumed.
The level of prealbumine before the LVAD implant was not associated with postimplant adverse events including bleeding, infection, stroke, renal failure, and RV
failure. In addition, lower prealbumin did not impact risk-adjusted 1-year mortality
when modeled either as a categorical or continuous variable.29
Pre-VAD abnormal pulmonary functions overall were not associated with inferior
outcomes, although patients in the lowest strata of forced expiratory volume in one
second (FEV1) (< 60% predicted) and FEV1/forced vital capacity (< 0.5) had
elevated risk-adjusted hazards for mortality (HR 2.63, 95% CI, 1.51-4.60 and HR
18.92, 95% CI, 2.10-170.40, respectively).30
The impact of smoking on LVAD outcomes was examined in several studies in 2020.
Former smokers had statistically comparable total readmission rates with never
smokers (2.49 vs. 2.13 event/year), whereas current smokers had significantly
higher rates compared to never smokers (2.81 events/year, P < .05). The rates of
driveline infection, stroke, and hemolysis were statistically comparable between the
never smokers and former smokers, while current smokers had significantly higher
rates compared to never smokers (P < .05 for all).31
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Additionally, active smoking was associated with higher rates of adverse events in
males, while females had a high rate of adverse events irrespective of smoking
status.32
Interestingly, a survey of VAD implanting centers revealed that only a third of them
(32%) consider smoking a deciding factor in destination therapy evaluations.33
Psychosocial evaluation is easily one of the most subjective tests patients have to
pass in order to become LVAD candidates. In the INTERMACS database, patients
were determined to have psychosocial risk if they had one of the following: (1) limited
social support; (2) limited cognition; (3) substance abuse (alcohol and drug); (4)
severe psychiatric disease (including major depression and other major psychiatric
diagnosis); and (5) repeated noncompliance. The most prevalent psychosocial risk
factor was substance abuse in 12.6% of recipients. Patients with psychosocial risk
were at increased hazards for device-related infection, GI bleeding, pump
thrombosis, and readmission and reduced hazards for cardiac transplantation (P <
.05 for all). However, the most important outcomes—survival on pump support or
stroke—were unaffected.34

Management of Patients on LVAD Support
Quality of Life
Patients on LVAD support have better hemodynamics and enjoy a better quality of
life than pre-VAD, but many limitations remain. A recent study by Fujino et al.35
showed that following LVAD implantation, pulmonary arterial pressure and
pulmonary capillary wedge pressure decreased, and cardiac index increased
significantly and then remained unchanged throughout follow-up. On the contrary,
right atrial pressure decreased initially and then gradually increased to pre-implant
values. The pulmonary artery pulsatility index (PAPI) decreased initially and
returned to pre-implant values, then progressively decreased over longer follow-up.
On cardiopulmonary stress test their peak VO2 averaged 10.6 ± 3.1 ml/kg/min,
indicating an inability to boost oxygen delivery to the muscles during exercise, which
is consistent with severe impairment of exercise capacity.36
In terms of emotional well-being, more patients with LVADs attempt or commit
suicide than healthy individuals or those with chronic medical conditions in general.
A study from the French registry, which has data on nearly 500 LVAD recipients,
reported that 10 patients (2%) attempted or committed suicide either by
unplugging/sectioning their LVAD cable or drug intoxication over 14 months of
follow-up. Only 2 of these patients had a previous history of psychiatric disorder
(depression with suicide attempt and schizophrenia). The variables associated with
suicide/suicidal attempt were DT LVAD and follow-up at a center without an LVAD
coordinator.37

Medical Management
ACE/ARBs/BB

In the annual literature review from last year,6 we emphasized the importance of
guideline directed medical therapy (GDMT) after the LVAD. The LVAD recipients
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with optimized hemodynamics have lower mortality38-41 and fewer complications. It
is of particular interest that they had not only fewer HF readmissions, which would
be intuitive, but also fewer hemocompatibility-related events such as bleeding and
thrombosis.41 An effort should be made to maximize favorable effects of
pharmacological management. Last year, another report demonstrated the
advantages of GDMT for RV function reflected in PAPI. Over the first year after
implant, patients who received BB and ACE/ARBs demonstrated higher PAPI than
patients not managed with these drugs (3.3 vs 1.6, P = .043 for BB and 3.4.vs 2.1,
P = .03 for ACE/ARBs). BB were also associated with reduced HF readmission, and
ACE/ARBs42 with reduced HF readmission and GI bleeding (P < .05 for all).42
Sacibutril/Valsartan
Reports on the use of sacibutril/valsartan in LVAD patients are of particular interest.
Three reports were published last year. The first experience with sacibutril/valsartan
was released and reviewed 5 patients. The tolerability of the drug was not very
favorable, with 3 out of 5 patients discontinuing the medication due to hypotensionrelated symptoms.43
At the Cleveland Clinic, 10 patients with LVADs and hypertension tolerated
sacibutril/valsartan for a median duration of 292 (141–422) days, and 4 of them
tolerated the high dose. Although mean blood pressure decreased by 20.0 ± 14.0
mmHg (P = .002), the dosage had to be reduced due to hypotension in only one
patient. As a result of being on sacibutril/valsartan, the daily diuretic requirement
decreased: furosemide oral equivalents decreased from 220.0 ± 167.9 mg to 120.0
± 94.3 mg, and N-terminal pro-B-type natriuretic peptide was reduced from 2929
pg/mL at baseline to 1530 pg/mL after a median of 19 (5–16) days of follow-up (P =
.36).44
In a retrospective study from several European countries, 22 LVAD (HM3 and
HVAD) patients were treated with sacibutril/valsartan for approximately 2 months.
Only a third of the patients had a mean arterial pressure > 90 mmHg. The moderate
dose of 49/51 mg twice daily was achieved in 86% of the patients.
Sacibutril/valsartan was effective in reducing the mean blood pressure (80 [73.5−92]
mmHg vs 75 [70−84.5] mmHg, P = .03) and it was related to an increased pump
flow (4.05 [3.57−4.52] vs 4.4 [3.70−4.65] liters per minute; P = .01). Left ventricular
end-diastolic dimension, inferior vena cava diameter, and N-terminal pro-B-type
natriuretic peptide decreased, as well as daily diuretic requirement. In addition, the
functional status improved. The proportion of patients in New York Heart Association
(NYHA) class I increased from 14.3% to 47.6% after sacibutril/valsartan initiation (P
= .002).45 Overall, the use of sacibutril/valsartan in the LVAD population looks
tolerable and promising.
Sildenafil
Two conflicting studies on the role of sildenafil in post-LVAD management were
published in 2020. According to the INTERMACS analysis, phosphodiesterase type
5 inhibitors in patients on LVAD support were associated with a lower rate of pump
thrombosis (HR, 0.82; 95% CI, 0.74-0.90; P < .001) and ischemic stroke (HR, 0.85;
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95% CI, 0.75-0.97; P =.019).46 On the other hand, a systematic review and metaanalysis of published studies found that sildenafil was not associated with lower
post-operative RV failure, GI bleeding, stroke, or pump thrombosis.47

Obesity
Management of obesity in the LVAD population remains a hot topic because many
patients need to lose weight in order to be listed for transplant. Bariatric surgery
remains a valid and sometimes the only option leading to success. In a systematic
review and meta-analysis on sleeve gastrectomy in LVAD recipients, it was found
that both surgeries are performed simultaneously in 37% of cases, while the
remaining cases were staged. The mean body mass index decreased from 46.7
kg/m2 (95% CI: 42.9-50.6) to 33.4 kg/m2 (95% CI: 30.2-36.6) (P < .01) over the
follow-up of 12.7 months. Bariatric surgery resulted in 66% of patients to be listed
for heart transplantation, including 33% (95% CI: 22-47) who were transplanted. The
outcomes of simultaneous versus staged surgeries were comparable.48 Similar
results were reported from published literature by Aelst et al.49 and deAbreu et al.50

Arrhythmia
While the discussions about the need for an implantable cardioverter-defibrillator
(ICD) in patients with an LVAD are ongoing, most patients have ICDs, and they need
to be interrogated on a regular basis. The electromagnetic interference between the
LVAD and ICD which prevents interrogation is not uncommon. In a retrospective,
multicenter, observational study of LVAD recipients with a transvenous lead ICD,
approximately 4% of patients’ ICDs could not be interrogated because of
interference. The interference occurred after a median of 19.0 (5.2 -88.0) days
following LVAD implantation, and 6%, 2%, and 1.5% occurred in patients implanted
with Abbott, Medtronic, and Biotronik devices, respectively (P < .001). In most
cases, patients had an HMII pump. The issue could sometimes be remedied by
placing a metal plate on the chest between the LVAD and ICD and placing a metal
box above the LVAD. In half of the cases, however, this did not work, and ICDs had
to be replaced.51 In another study, this type of interference was reported in 13% of
the patients. They were implanted with HMII and HM3 pumps, and the interference
usually occurred between an HMII and Abbott ICD and between the HM3 and
Biotronik ICD; rarely was interference reported with Medtronic devices.52
In one case, when an in-office interrogation was unsuccessful due to
electromagnetic interference, the patient was instructed to extend his arm above his
head on the ipsilateral side of the ICD, thereby increasing the distance between the
LVAD and ICD. This eliminated the interaction and allowed for reprogramming of
the device.53
Subcutaneous ICDs have become a popular option for LVAD- supported patients.
Because it does not have intracardiac leads, the risk of infection is lower than in
transvenous defibrillators. In subcutaneous devices, sensing relies on good
discrimination between P, R, and T waves, which can be altered after LVAD
implantation. When tested for an adequate electrocardiogram signal, more than
70% of patients with an LVAD were eligible for a subcutaneous ICD.54
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Interference also occurs between subcutaneous ICDs and LVADs and manifests in
inappropriate shocks. In a study by Ishida et al., interference was reported in
patients with HM3 and HVAD devices. In some patients, the problem could be
resolved by reprogramming the ICD to an alternate vector, but some defibrillators
had to be replaced.55 Duke researchers found such interference to be quite
common.56
Another topic on the crossroads between MCS and electrophysiology is the
relationship between arrhythmias and mechanical unloading. In the study from the
Dresden Impella Registry, all 19 patients with cardiogenic shock and arrhythmias
refractory to electrical defibrillation or antiarrhythmic drugs, were able to stop their
arrhythmia after implantation of a micro-axial heart pump. This phenomenon was
referred to as heart rhythm stabilization.57
Although V-A ECMO does not treat ventricular tachycardia, it effectively provides a
hemodynamic bridge to support patients until electrical instability is treated or
subsides on its own, like in acute ischemic cardiomyopathy. In a retrospective study
from two French centers, 83 patients were on ECMO for a treatment-refractory
electrical storm. Of this cohort, 59% had acute ischemic cardiomyopathy and 66%
underwent cardiopulmonary resuscitation prior to ECMO, with 18% cannulated
during the procedure. Fifty patients (60%) had ventricular tachycardia and/or
ventricular fibrillation alternating with short periods of sinus rhythm, and 33 (40%)
had refractory ventricular tachycardia and/or ventricular fibrillation. Catheter ablation
was performed in 15% of the patients, 45% were successfully weaned off, and 42%
were alive 6 months post-admission. The median time on support was 3 days (1-13
days).58
The most common procedure for termination of refractory ventricular tachycardia is
ablation. Ablation procedures can be lengthy and cause myocardial stunning and
hemodynamic compromise in already decompensated patients with severe
cardiomyopathy. In a systematic review on MCS for life-threatening arrhythmia,
Mariani et al.59 found that survival after ablation for electrical storm is higher with
prophylactic use of MCS for hemodynamic support. Patients with prophylactically
used MCS also had higher rates of termination and non-inducibility of ventricular
tachycardia after ablation.
Ablations are also performed in ventricular tachycardia in LVAD recipients. Grinstein
et al.60 used a composite outcome of adverse events to analyze the ablation
procedure's impact. They found that 58% of patients who had ablation while on
LVAD suffered an adverse event during a one-year follow up (11%--confirmed pump
thrombosis; 41%--suspected pump thrombosis; 39%-- thromboembolic events
including stroke). This rate was significantly higher (P = .002) than the 30% rate of
adverse events in patients with an LVAD and ventricular tachycardia but treated
without ablation.60

Complications of the VADs
Stroke
Stroke is a devastating complication of an LVAD, and everything that may prevent
it should be utilized. In a single-center, retrospective study, statins were associated
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with a reduced rate of cerebrovascular accidents. In patients receiving statins,
strokes occurred at the rate of 0.11 events per patient-year while the rate for those
not on a statin was 0.22 events per patient-year (age-adjusted HR 0.46; 95% CI =
0.24-0.88; P = .019). The difference was determined by ischemic strokes, because
the rate of hemorrhagic strokes was similar regardless of statin use.60

Gastrointestinal Bleeding
Almost every year, there is a new report on a novel pharmacological therapy for
prevention of GI bleeding in patients on LVAD support. In 2020, bevacizumab was
found to be such a therapy. Patients were given 8-18 infusions intravenously
during the study period. Median follow-up time after bevacizumab initiation was
21.7 months. Four out of five patients had a complete response, and the last
patient achieved a partial response. Treatment with intravenous bevacizumab
resulted in a significant reduction in the number of blood transfusions from the
median 56.5 to 6.6 red blood cell units per year, P = .035. Similarly, the median
number of bleeding-related hospitalizations decreased from 5.4 to 1.7 per year, P
= .041. The requirements in endoscopic procedures were also reduced.61
In another series of 8 patients with frequent GI bleeding, success was achieved
with the use of tamoxifen. Tamoxifen was associated with a significant decrease in
major GI bleedings from a median of 3 (IQR 1.4-7) events/patient-year pretamoxifen initiation to 0 (IQR 0-0.9) events/patient-year post-tamoxifen initiation (P
= .02). Transfusion of packed red blood cells also decreased from 16.8 (IQR 9.930.6) units/patient-year pre-tamoxifen initiation to 1.5 (IQR 0-7.5) units/patient-year
post-tamoxifen (P = .04).62

Different Devices
Intra-Aortic Balloon Pump
A new organ allocation system for heart transplantation favors patients on shortand intermediate-term MCS, and several studies reported an increase of
temporary MCS use in listed patients since the end of 2018 when the new policy
came into effect.63 Since the goal is to keep patients ambulatory while they wait for
the donor heart, use of the axillary artery as a site of implantation is very attractive
for clinicians. However, positioning the balloon pump at this site is prone to
complications. Bhimaraj et al.64 published a paper about their experience with
axillary intra-aortic balloon pumps. The procedure was successful in 68% of their
195 cases; 120 patients were BTT and 13 patients received LVADs. The pump
required frequent bedside repositioning, and 37% of the pumps had to be replaced
for malfunction. The rate of complications was quite high. Specifically, 15.8%
required 1 exchange, 8.7%-2 exchanges, 4.6%-3 exchanges, 3%- 4 exchanges,
1% -5 exchanges, and 1 patient needed 7 exchanges.64

Impella
For the same reasons, axillary Impella (Abiomed, Danvers, MA) is increasingly
being used. In a cohort of 40 patients with cardiogenic shock, the duration of
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support on this device was 21.05 ± 17 days. Half of the patients died during the
same admission, and 17% had complications from the Impella including right arm
ischemia or neuropathy (7.5%) and pump malfunction requiring device
replacement (10%).65

What is New in V-A ECMO World?
In the V-A ECMO world, the issue of venting the LV for prevention or treatment of
LV distension and pulmonary edema continues to be an actively discussed topic.
While V-A ECMO is a life-saving method for patients with low-output failure surgery,
this therapy may increase LV afterload due to retrograde blood flow in the aorta,
which may lead to progression of pulmonary congestion.
Prognostic significance of this complication is not well established. In our paper
about “white lungs” on V-A ECMO, we showed that in patients who did not have
severe pulmonary congestion, survival to weaning off V-A ECMO and survival to
hospital discharge were 91.7% and 66.7%, respectively. In those with white lungs,
the corresponding values were 50.0% and 26.5%, respectively (P = .019 for
discharged alive).66
In 2020, Distelmaier et al.67 examined the predictive value of pulmonary congestion
in patients that need V-A ECMO support after cardiovascular surgery.
When evaluated progressively during ECMO support, pulmonary edema on the first
day was not associated with poor prognosis, but if the congestion was present on
the 3rd or the 5th day of support, it was significantly associated with survival
(adjusted HR 2.81; 95%-CI 1.76-4.46, P < .001, and HR 3.01; 95%-CI 1.84-4.93, P
< .001, respectively). Linear regression revealed that only ECMO output (not LV
function, cardiac output, central venous saturation, maximum dobutamine, and
norepinephrine dose or fluid balance) was associated with the evolution of
pulmonary congestion (P = .007).67
There are multiple ways to unload (vent) the LV. We gave a detailed review of
different solutions for this problem in 2018.4 In 2020, different methods were
compared with the use of a mock circulatory loop with simulated acute LV failure on
ECMO support. A surgically placed LV vent and temporary LVAD provided the most
complete unloading in terms of reduction of LV diastolic volume. The temporary VAD
was also the best for reduction in left atrial pressure from 13.3 to 4.4 mm Hg. The
pulmonary artery surgical vent was the most effective at reducing mean pulmonary
arterial pressure from 21.0 to 10.6 mm Hg.68 In another model, Impella has a higher
capability of LV unloading than atrial septal defect.69
The Impella device increases the forward flow from the LV into the aorta and
remains one of the most popular ways to unload the LV. In an international,
multicenter cohort study, LV unloading with Impella, which was used in 49% of
patients on V-A ECMO due to cardiogenic shock, was associated with a lower 30day mortality (HR, 0.79 [95% CI, 0.63-0.98]; P = .03), despite higher complication
rates.70
One of the ideas brought up in 2020 was inserting an additional catheter into the
pulmonary artery and connecting it to the venous arm of V-A ECMO.71
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Although there is no universal age limit for initiation of V-A ECMO, most programs
put arbitrary restrictions because of lower survival in older age groups. However,
ECMO may be an option for elderly patients. The analysis of three age groups (7074, 75-79, and ≥ 80 years of age) showed that in the whole cohort, 46.7% were
weaned off ECMO. Overall in-hospital mortality was estimated at 68.3% with highest
crude mortality rates observed in the 75-79 year-old subgroup (70.1%).
Characteristically, nearly 100% mortality was observed when ECMO was used for
sepsis.72
Overall, 2020 was a productive year with many new developments. We hope to
expand on them in 2021.

References:
1.
Guglin M. What did we learn about VADs in 2014? The VAD Journal.
2015;1:e201513.
2.
Guglin M. What did we learn about VADs in 2015? . The VAD Journal.
2016;2:e201622.
3.
Guglin M. What did we learn about VADs in 2016? The VAD Journal.
2017;3:e201731.
4.
Guglin M. What did we learn about VADs in 2017? . The VAD Journal.
2018;4:e201844.
5.
Guglin M. What did we learn about VADs in 2018? The VAD Journal.
2019;5:e201953.
6.
Guglin M. What did we learn about VADs in 2019? The VAD Journal.
2020;6(1):e2020616.
7.
Teuteberg JJ, Cleveland JC, Jr., Cowger J, et al. The Society of Thoracic
Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices
and Indications. Ann Thorac Surg. 2020;109(3):649-60.
8.
Mueller M, Hoermandinger C, Richter G, et al. Retrospective 1-year
outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left
ventricular assist devices in a single centre. Eur J Cardiothorac Surg.
2020;57(6):1160-5.
9.
Schramm R, Zittermann A, Morshuis M, et al. Comparing short-term
outcome after implantation of the HeartWare(R) HVAD(R) and the Abbott(R)
HeartMate 3(R). ESC Heart Fail. 2020;7(3):908-14.
10.
Carrier M, Moriguchi J, Shah KB, et al. Outcomes after heart
transplantation and total artificial heart implantation: A multicenter study. J Heart
Lung Transplant. 2021;40(3):220-8.
11.
Zimpfer D, Gustafsson F, Potapov E, et al. Two-year outcome after
implantation of a full magnetically levitated left ventricular assist device: results
from the ELEVATE Registry. Eur Heart J. 2020;41(39):3801-9.
12.
Saeed O, Colombo PC, Mehra MR, et al. Effect of aspirin dose on
hemocompatibility-related outcomes with a magnetically levitated left ventricular
The VAD Journal: Review of 2020

Page 14 of 19

The VAD Journal: The journal of mechanical assisted circulation and heart failure

assist device: An analysis from the MOMENTUM 3 study. J Heart Lung
Transplant. 2020;39(6):518-25.
13.
Lim HS, Ranasinghe A, Chue C, Mascaro J. Two-year outcome of warfarin
monotherapy in HeartMate 3 left ventricular assist device: A single-center
experience. J Heart Lung Transplant. 2020;39(10):1149-51.
14.
Imamura T, Narang N, Nitta D, et al. Optimal cannula positioning of
HeartMate 3 left ventricular assist device. Artif Organs. 2020;44(12):e509-e19.
15.
Imamura T, Narang N, Nitta D, et al. HeartWare Ventricular Assist Device
Cannula Position and Hemocompatibility-Related Adverse Events. Ann Thorac
Surg. 2020;110(3):911-7.
16.
Zimpfer D, Fiane AE, Larbalestier R, et al. Long-Term Survival of Patients
With Advanced Heart Failure Receiving an Left Ventricular Assist Device Intended
as a Bridge to Transplantation: The Registry to Evaluate the HeartWare Left
Ventricular Assist System. Circ Heart Fail. 2020;13(3):e006252.
17.
Al Masri E, Al Shakaki M, Welp H, Scherer M, Dell'Aquila AM. Long-term
follow-up of patients supported with the HeartWare left ventricular assist system.
Artif Organs. 2020;44(10):1061-6.
18.
Marasco S, Simon AR, Tsui S, et al. International experience using a
durable, centrifugal-flow ventricular assist device for biventricular support. J Heart
Lung Transplant. 2020;39(12):1372-9.
19.
Maynes EJ, O'Malley TJ, Patel P, et al. Right atrial versus right ventricular
HeartWare HVAD position in patients on biventricular HeartWare HVAD support: A
systematic review. Artif Organs. 2020;44(9):926-34.
20.
Sorensen EN, Dees LM, Kaczorowski DJ, Feller ED. The Heartware
Lavare Cycle: A Cautionary Tale. ASAIO J. 2020;66(9):e114-e6.
21.
Chaudhry UI, Kanji A, Sai-Sudhakar CB, Higgins RS, Needleman BJ.
Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart
failure and left ventricular assist device: medium-term results. Surg Obes Relat
Dis. 2015;11(1):88-93.
22.
Antonides CFJ, Schoenrath F, de By T, et al. Outcomes of patients after
successful left ventricular assist device explantation: a EUROMACS study. ESC
Heart Fail. 2020;7(3):1085-94.
23.
Drakos SG, Wever-Pinzon O, Selzman CH, et al. Magnitude and time
course of changes induced by continuous-flow left ventricular assist device
unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol.
2013;61(19):1985-94.
24.
Kassner A, Oezpeker C, Gummert J, et al. Mechanical circulatory support
does not reduce advanced myocardial fibrosis in patients with end-stage heart
failure. Eur J Heart Fail. 2021;23(2):324-34.
25.
Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug
therapy for the reversal of heart failure. N Engl J Med. 2006;355(18):1873-84.

The VAD Journal: Review of 2020

Page 15 of 19

The VAD Journal: The journal of mechanical assisted circulation and heart failure

26.
George I, Xydas S, Mancini DM, et al. Effect of clenbuterol on cardiac and
skeletal muscle function during left ventricular assist device support. J Heart Lung
Transplant. 2006;25(9):1084-90.
27.
Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with
a continuous-flow left ventricular assist device and pharmacological therapy: a
prospective study. Circulation. 2011;123(4):381-90.
28.
Birks EJ, Drakos SG, Patel SR, et al. Prospective Multicenter Study of
Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF
[Remission from Stage D Heart Failure]): Medium-Term and Primary End Point
Results. Circulation. 2020;142(21):2016-28.
29.
Hong Y, Seese L, Hickey G, Mathier M, Thoma F, Kilic A. Preoperative
prealbumin does not impact outcomes after left ventricular assist device
implantation. J Card Surg. 2020;35(5):1029-36.
30.
Hess NR, Seese LM, Hickey GW, et al. The predictive value of preimplant
pulmonary function testing in LVAD patients. J Card Surg. 2021;36(1):105-10.
31.
Combs P, Imamura T, Siddiqi U, et al. Effect of tobacco smoking on
outcomes after left ventricular assist device implantation. Artif Organs.
2020;44(7):693-9.
32.
Imamura T, Combs P, Siddiqi U, et al. Sex difference in the impact of
smoking on left ventricular assist device outcomes. J Card Surg.
2020;35(11):2913-9.
33.
Combs P, Cohen W, Siddiqi UA, Jeevanandam V. An international survey:
Tobacco smoking cessation strategies within left ventricular assist device centers.
Int J Artif Organs. 2021;44(2):110-4.
34.
DeFilippis EM, Breathett K, Donald EM, et al. Psychosocial Risk and Its
Association With Outcomes in Continuous-Flow Left Ventricular Assist Device
Patients. Circ Heart Fail. 2020;13(9):e006910.
35.
Fujino T, Sayer A, Nitta D, et al. Longitudinal Trajectories of
Hemodynamics Following Left Ventricular Assist Device Implantation. J Card Fail.
2020;26(5):383-90.
36.
Moss N, Rakita V, Lala A, et al. Hemodynamic Response to Exercise in
Patients Supported by Continuous Flow Left Ventricular Assist Devices. JACC
Heart Fail. 2020;8(4):291-301.
37.
Charton M, Flecher E, Leclercq C, et al. Suicide Attempts Among LVAD
Recipients: Real-Life Data From the ASSIST-ICD Study. Circulation.
2020;141(11):934-6.
38.
McCullough M, Caraballo C, Ravindra NG, et al. Neurohormonal Blockade
and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular
Assist Devices. JAMA Cardiol. 2020;5(2):175-82.
39.
Yousefzai R, Brambatti M, Tran HA, et al. Benefits of Neurohormonal
Therapy in Patients With Continuous-Flow Left Ventricular Assist Devices. ASAIO
J. 2020;66(4):409-14.

The VAD Journal: Review of 2020

Page 16 of 19

The VAD Journal: The journal of mechanical assisted circulation and heart failure

40.
Vaidya G, Birks E, Pillarella J, et al. Effects of beta blockers and ACE
inhibitors after left ventricular assist device implantation. The VAD Journal.
2018;4:e201849.
41.
Imamura T, Nguyen A, Kim G, et al. Optimal haemodynamics during left
ventricular assist device support are associated with reduced haemocompatibilityrelated adverse events. Eur J Heart Fail. 2019;21(5):655-62.
42.
Imamura T, Mehta P, Nguyen A, et al. Neurohormonal Blockade During
Left Ventricular Assist Device Support. ASAIO J. 2020;66(8):881-5.
43.
Sharma A, Moayedi Y, Duclos S, Teuteberg J, Banerjee D. Tolerability of
Sacubitril/Valsartan in Patients With Durable Left Ventricular Assist Devices.
ASAIO J. 2020;66(3):e44-e5.
44.
Randhawa VK, West L, Luthman J, Estep JD, Soltesz EG, Starling RC.
Sacubitril/valsartan in patients post-left ventricular assist device implant: a singlecentre case series. Eur J Heart Fail. 2020;22(8):1490-2.
45.
Dobarro D, Diez-Lopez C, Couto-Mallon D, et al. Use of sacubitril-valsartan
in blood pressure control with left ventricular assist devices. J Heart Lung
Transplant. 2020;39(12):1499-501.
46.
Xanthopoulos A, Tryposkiadis K, Triposkiadis F, et al. Postimplant
Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of
Thrombotic Events After Left Ventricular Assist Device Implantation. J Am Heart
Assoc. 2020;9(14):e015897.
47.
Kittipibul V, Blumer V, Angsubhakorn N, et al. Phosphodiesterase-5
Inhibitors and Outcomes During Left Ventricular Assist Device Support: A
Systematic Review and Meta-Analysis. J Card Fail. 2021;27(4):477-85.
48.
Challapalli J, Maynes EJ, O'Malley TJ, et al. Sleeve Gastrectomy in
Patients with Continuous-Flow Left Ventricular Assist Devices: a Systematic
Review and Meta-Analysis. Obes Surg. 2020;30(11):4437-45.
49.
Van Aelst P, Deleus E, Van der Schueren B, Meyns B, Vandersmissen K,
Lannoo M. Laparoscopic Sleeve Gastrectomy in Patients with Left Ventricular
Assist Device-Case Series and Review of Literature. Obes Surg. 2020;30(9):362833.
50.
daSilva-deAbreu A, Alhafez BA, Curbelo-Pena Y, et al. Bariatric Surgery in
Patients with Obesity and Ventricular Assist Devices Considered for Heart
Transplantation: Systematic Review and Individual Participant Data Meta-analysis.
J Card Fail. 2021;27(3):338-48.
51.
Galand V, Leclercq C, Boule S, et al. Implantable Cardioverter- Defibrillator
Interference After LVAD Implantation. JACC Clin Electrophysiol. 2020;6(10):13157.
52.
Yalcin YC, Kooij C, Theuns D, et al. Emerging electromagnetic
interferences between implantable cardioverter-defibrillators and left ventricular
assist devices. Europace. 2020;22(4):584-7.
53.
Jin C, Hsu J, Frenkel D, Jacobson JT, Iwai S, Ferrick A. Unique technique
to relieve left ventricular assist device electromagnetic interference with an

The VAD Journal: Review of 2020

Page 17 of 19

The VAD Journal: The journal of mechanical assisted circulation and heart failure

implantable cardioverter defibrillator. J Cardiovasc Electrophysiol. 2021;32(2):5513.
54.
Zormpas C, Silber-Peest AS, Eiringhaus J, et al. Eligibility for
subcutaneous implantable cardioverter-defibrillator in adults with congenital heart
disease. ESC Heart Fail. 2021;8(2):1502-8.
55.
Ishida Y, Payne JE, Field ME, Gold MR. Electromagnetic interference from
left ventricular assist devices in patients with subcutaneous implantable
cardioverter-defibrillators. J Cardiovasc Electrophysiol. 2020;31(5):1195-201.
56.
Black-Maier E, Lewis RK, Barnett AS, et al. Subcutaneous implantable
cardioverter-defibrillator troubleshooting in patients with a left ventricular assist
device: A case series and systematic review. Heart Rhythm. 2020;17(9):1536-44.
57.
Mierke J, Loehn T, Ende G, et al. Percutaneous Left Ventricular Assist
Device Leads to Heart Rhythm Stabilisation in Cardiogenic Shock: Results from
the Dresden Impella Registry. Heart Lung Circ. 2021;30(4):577-84.
58.
Baudry G, Sonneville R, Waintraub X, et al. Extracorporeal Membrane
Oxygenation to Support Life-Threatening Drug-Refractory Electrical Storm. Crit
Care Med. 2020;48(10):e856-e63.
59.
Mariani S, Napp LC, Lo Coco V, et al. Mechanical circulatory support for
life-threatening arrhythmia: A systematic review. Int J Cardiol. 2020;308:42-9.
60.
Vieira JL, Pfeffer M, Claggett BL, et al. The impact of statin therapy on
neurological events following left ventricular assist system implantation in
advanced heart failure. J Heart Lung Transplant. 2020;39(6):582-92.
61.
Asleh R, Albitar HAH, Schettle SD, et al. Intravenous bevacizumab as a
novel treatment for refractory left ventricular assist device-related gastrointestinal
bleeding. J Heart Lung Transplant. 2020;39(5):492-5.
62.
Plazak ME, Hankinson SJ, Sorensen EN, Reed BN, Ravichandran B, Ton
VK. Novel Use of Tamoxifen to Reduce Recurrent Gastrointestinal Bleeding in
Patients with Left Ventricular Assist Devices. J Cardiovasc Transl Res. 2020.
63.
Trivedi JR, Slaughter MS. "Unintended" Consequences of Changes in
Heart Transplant Allocation Policy: Impact on Practice Patterns. ASAIO J.
2020;66(2):125-7.
64.
Bhimaraj A, Agrawal T, Duran A, et al. Percutaneous Left Axillary Artery
Placement of Intra-Aortic Balloon Pump in Advanced Heart Failure Patients. JACC
Heart Fail. 2020;8(4):313-23.
65.
Tarabichi S, Ikegami H, Russo MJ, Lee LY, Lemaire A. The role of the
axillary Impella 5.0 device on patients with acute cardiogenic shock. J
Cardiothorac Surg. 2020;15(1):218.
66.
Guglin M, Burchett A, Tribble T, Charnigo R. Pulmonary congestion (white
lungs) on VA ECMO. The VAD Journal. 2016;2:e201624.
67.
Distelmaier K, Wiedemann D, Lampichler K, et al. Interdependence of VAECMO output, pulmonary congestion and outcome after cardiac surgery. Eur J
Intern Med. 2020;81:67-70.

The VAD Journal: Review of 2020

Page 18 of 19

The VAD Journal: The journal of mechanical assisted circulation and heart failure

68.
Stephens AF, Wanigasekara D, Pellegrino VA, et al. Comparison of
Circulatory Unloading Techniques for Venoarterial Extracorporeal Membrane
Oxygenation. ASAIO J. 2020.
69.
Di Molfetta A, Adachi I, Ferrari G, et al. Left ventricular unloading during
extracorporeal membrane oxygenation - Impella versus atrial septal defect: A
simulation study. Int J Artif Organs. 2020;43(10):663-70.
70.
Schrage B, Becher PM, Bernhardt A, et al. Left Ventricular Unloading Is
Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With
Venoarterial Extracorporeal Membrane Oxygenation: Results From an
International, Multicenter Cohort Study. Circulation. 2020;142(22):2095-106.
71.
de Pommereau A, Radu C, Boukantar M, et al. Left Ventricle Unloading
Through Pulmonary Artery in Patients With Venoarterial Extracorporeal Membrane
Oxygenation. ASAIO J. 2021;67(1):e49-e51.
72.
Kowalewski M, Zielinski K, Maria Raffa G, et al. Mortality Predictors in
Elderly Patients With Cardiogenic Shock on Venoarterial Extracorporeal Life
Support. Analysis From the Extracorporeal Life Support Organization Registry. Crit
Care Med. 2021;49(1):7-18.

The VAD Journal: Review of 2020

Page 19 of 19

